Under-a-dollar shares of DOR BioPharma Inc. lost more than half their value after the FDA issued a not approvable letter for orBec, a steroid-sparing agent, citing the need for further efficacy and safety data in patients with gastrointestinal graft-vs.-host disease, a complication of hematopoietic cell transplantation. (BioWorld Today) Read More
